Innovent Biologics, Adimab deal

Adimab and Innovent expanded a 2013 deal to use Adimab’s yeast-based antibody discovery technology. Under the expanded deal, Adimab will over three years generate IgGs or bispecific antibodies for development as therapeutic products for multiple targets selected by Innovent. Innovent retains worldwide commercialization rights to resulting products. Innovent declined to disclose financial terms. Adimab did not respond to inquiries. ...